+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 11 Actively Recruiting clinical trials

S

Actively Recruiting

Researchers are evaluating the safety and effects of a new drug called NNC0487-0111 in people with Heart Failure with preserved Ejection Fraction HFpEF or Heart Failure with mildly reduced Ejection Fraction HFmrEF who also have excess body weight. This study compares NNC0487-0111 against a placebo to determine if it is safe and effective for treating these heart conditions in people with obesity. The study is a randomized, controlled trial conducted by Novo Nordisk AS. Participants will receive either NNC0487-0111 or a placebo by subcutaneous injection once a week. The study drug dose may increase over time for those receiving NNC0487-0111. Treatment assignment is random, and the study includes a parallel design with two groups one receiving the experimental drug and one receiving placebo. The treatment period and monitoring last up to 165 weeks. During the study, participants will be monitored for heart failure events, cardiovascular death, hospital visits related to heart failure, and other major cardiovascular outcomes. They will complete questionnaires about their heart failure symptoms and quality of life. Kidney function will also be assessed in some participants. Safety and effectiveness will be evaluated throughout the study period, which can last over three years, with regular visits for injections and assessments.

Age: 18Years +All GendersPhase 3
838 locations
S

Actively Recruiting

Researchers are investigating the relationship between chronic non-cancer pain and chronic insomnia, two conditions that often occur together and negatively impact quality of life. Chronic pain lasts more than three months and affects about 17% of adults in Spain, while chronic insomnia involves persistent trouble with sleep at least three times a week for three months or more. This study aims to estimate how common chronic insomnia is among adults suffering from chronic non-cancer pain, addressing an important gap in current knowledge. The study involves adult patients with chronic non-cancer pain who are receiving usual care from pain specialists or within dedicated pain units in outpatient settings. Participants will be observed to determine the prevalence of chronic insomnia and related factors, without any experimental treatments or interventions. All data collection will occur during a baseline visit. Participants will attend a baseline visit where they will be assessed for the presence of chronic insomnia, pain intensity, sleep quality, anxiety, depression, mood, well-being, functional capacity, and use of sleep-related medications. Researchers will collect these measurements to understand the overlap of insomnia and chronic pain and their impact on patients. The study will provide important information to help develop better integrated treatments for managing pain and sleep problems together.

Age: 18Years +All Genders
15 locations
P

Actively Recruiting

Researchers are evaluating whether adding Hyperthermic Intraperitoneal Chemotherapy HIPEC with Mitomycin C after complete surgical removal of peritoneal metastases in patients with colon cancer affects the chance of cancer returning in the abdomen. This phase IV clinical trial addresses uncertainties from prior research by focusing on the time patients remain free from peritoneal recurrence rather than overall survival. It excludes rectal cancers and patients with extensive peritoneal disease or incomplete surgery to better understand HIPECs role in this setting. Participants are randomly assigned to one of two groups one receiving complete cytoreductive surgery plus HIPEC with Mitomycin C delivered at 35 mgm2 in a heated peritoneal dialysis solution for 90 minutes with dose fractionation, and the other receiving surgery alone without HIPEC. The study corrects previous trial shortcomings by increasing HIPEC infusion time and limiting patient selection based on cancer spread and surgery completeness. During the trial, participants will be monitored for peritoneal recurrence over three years, with assessments including imaging and disease-free survival measures. Researchers will also track postoperative complications within 90 days after surgery and evaluate quality of life at multiple points before surgery, after chemotherapy, and at one and two years. The trial aims to provide detailed information on recurrence patterns, survival, and patient well-being over three years following treatment.

Age: 18Years +All GendersPhase 4
31 locations
C

Actively Recruiting

Researchers are collecting detailed information about patients with venous thromboembolism VTE to improve understanding of this condition, especially in groups often excluded from clinical trials such as pregnant women, elderly patients, and those with severe health issues. This observational registry aims to provide data that can help reduce death rates, recurrences of blood clots, bleeding problems, and arterial events related to VTE. This study gathers clinical details about each patient, including other health conditions, and tracks the type, dose, duration, and results of antithrombotic treatments over the first three months. The registry is accessible online to assist doctors in managing complex cases by comparing patient profiles and identifying those at higher risk of complications. Participants clinical status and treatment outcomes are recorded, focusing on recurrence of VTE, bleeding events, and mortality over a three-year period. The information supports the creation of predictive scores to help healthcare providers identify patients at higher risk. The study started in 2001 and plans to continue until 2027, with ongoing data collection and follow-up.

All AgesAll Genders
305 locations
A

Actively Recruiting

Researchers are evaluating the presence of remaining fluid buildup, known as residual congestion, in patients hospitalized for acute heart failure. The study aims to assess this condition at the time of hospital discharge using multiple methods and compare how well each method predicts patient outcomes. Artificial intelligence will also be used to develop a new predictive model that may improve on standard approaches. The study involves measuring residual congestion through clinical signs such as orthopnea, jugular venous distension, and leg swelling imaging tests including non-invasive heart pressure measurements, lung ultrasound, and venous excess ultrasound scores and laboratory tests of various blood markers like NT-proBNP, hemoglobin, and others. All assessments are made at discharge to gather comprehensive data on fluid overload. Participants will be monitored for up to six months after leaving the hospital. During this time, researchers will track worsening heart failure, cardiovascular death, other heart failure events, and overall survival. The study includes regular evaluations of clinical signs, imaging, and laboratory tests to understand which evaluation methods best predict patient outcomes and to support the development of the new AI-based prognostic tool.

Age: 18Years +All Genders
1 location
C

Actively Recruiting

Researchers are evaluating two imaging methods, laparoscopic ultrasound LUS and fluorescence cholangiography with indocyanine green ICG, to identify biliary anatomy during technically challenging laparoscopic gallbladder removal surgery. This multicenter, prospective, interventional clinical trial aims to compare the success of these techniques in detecting critical junctions of bile ducts, which is important for patient safety during surgery. Participants will undergo both imaging tests during their gallbladder surgery in a set order first LUS, then fluorescence cholangiography before the key surgical dissection. This allows direct comparison of the two methods within the same procedure. The study focuses on patients who have anticipated surgical difficulty due to conditions like acute cholecystitis, prior abdominal surgeries, or obesity. During the study, researchers will monitor how clearly each imaging method identifies important bile duct junctions, how long it takes to visualize these structures, total surgery time, and any complications during or after surgery. The study also involves tracking patient outcomes intraoperatively and postoperatively to assess safety and effectiveness. Participation begins with surgery and includes follow-up for these measures.

Age: 18Years +All GendersPhase Not Applicable
1 location
E

Actively Recruiting

Researchers are evaluating the combination of baxdrostat and dapagliflozin compared with dapagliflozin alone in adults aged 40 years and older who have type 2 diabetes, established cardiovascular disease, a history of hypertension with elevated systolic blood pressure, and at least one additional risk factor for heart failure. This phase III trial aims to assess whether adding baxdrostat can reduce the risk of heart failure events or cardiovascular death. Participants will be randomly assigned to receive either baxdrostat with dapagliflozin or placebo with dapagliflozin. Those not currently on SGLT2 inhibitors or treated for less than 4 weeks will enter a run-in period taking dapagliflozin alone for 4 to 6 weeks before randomization. Doses of baxdrostat may be increased if criteria are met. Study visits occur at 2, 4, 8, 16, and 34 weeks after randomization and then approximately every 4 months until the study ends when enough cardiovascular events have occurred. During the study, participants will have regular assessments including blood pressure and laboratory tests to monitor safety and efficacy. If participants stop the blinded study treatment early, they may continue open-label dapagliflozin. The main outcome is to see if the combination reduces heart failure events or cardiovascular death compared to dapagliflozin alone, with follow-up lasting up to 38 months. Data collection and scheduled visits will continue throughout the study period.

Age: 40Years +All GendersPhase 3
977 locations
C

Actively Recruiting

Crohns disease CD often leads to stenosis, a common complication that increases risks like repeated surgery and short bowel syndrome. This study focuses on patients with new de novo stenosis less than 10 cm in length, seeking to compare the effectiveness, complications, quality of life impact, and costs of surgical versus endoscopic treatments. There is currently no clear scientific evidence guiding the best treatment choice for these patients. The study compares two endoscopic treatmentsendoscopic balloon dilation EBD and self-expanding metal stents SEMSagainst surgical resection for managing de novo stenosis in CD. Participants in the endoscopic groups receive either pneumatic balloon dilations up to twice with intervals or placement of fully coated metal stents for four weeks. Surgical resection is also evaluated, with all procedures including post-procedural monitoring in a Short Stay Unit and sedation as appropriate. Participants will be followed for one year, during which their quality of life, clinical recurrence, and complications will be assessed. Evaluations include endoscopic and radiological tests to confirm stenosis and ongoing monitoring of symptoms. The study also considers treatment costs and long-term efficacy. The overall aim is to better understand which treatment approach offers the best balance of safety, effectiveness, quality of life, and cost for patients with CD-related stenosis.

Age: 18Years - 80YearsAll GendersPhase Not Applicable
16 locations
O

Actively Recruiting

Researchers are evaluating how well brentuximab vedotin combined with cyclophosphamide, doxorubicin, and prednisone CHP works and how safe it is as a first treatment for adults with CD30-positive peripheral T-cell lymphoma in Spain. This observational study collects information from patients who have already received this treatment as part of routine care to understand real-world outcomes and side effects. The study is led by the Grupo Espaol de Linfomas y Trasplante Autlogo de Mdula sea. Participants received brentuximab vedotin plus CHP as their first-line therapy between January 2019 and September 2024 according to usual medical practice. This study does not assign or change treatments but reviews patient medical records retrospectively to evaluate treatment effectiveness and safety across multiple centers in Spain. During the study, researchers will measure how long participants live without their lymphoma worsening progression-free survival over up to about 68 months. They will also assess how well the treatment shrinks or eliminates lymphoma, overall survival, side effects including nerve problems and low white blood cell counts, and other outcomes like PETCT scan responses and lymphoma subtype impact. Information is gathered from existing medical records, and the study does not involve new treatments or procedures for participants.

Age: 18Years +All Genders
37 locations
G

Actively Recruiting

Researchers are evaluating whether a treatment strategy guided by the Remote Dielectric Sensing ReDS device is better than the current usual care for adults hospitalized with heart failure. The study also aims to assess the safety and cost-effectiveness of this ReDS-guided approach. The goal is to see if this strategy can reduce the risk of cardiovascular events within the first month after hospital discharge and to understand its safety profile. Participants will be randomly assigned to one of two groups. In the ReDS-guided group, clinicians will use daily ReDS measurements to adjust treatment following a specific diuretic protocol until stability and lung fluid reduction criteria are met. The control group will receive usual care without access to ReDS data, with treatment decisions based on clinical judgment and local practice. Patients will remain hospitalized until clinical stability is achieved according to defined criteria, including weight loss, biomarker reduction, and edema score. After discharge, all participants will have two follow-up visits at 2 weeks and 30 days. During the study, participants will undergo daily lung fluid assessments using the ReDS device while hospitalized. Researchers will monitor the number of cardiovascular events and safety issues within one month after discharge. They will also track hospital stay length to evaluate cost-effectiveness. Follow-up visits at 2 weeks and 30 days will include assessments to measure these outcomes. The total participation period covers hospitalization plus one month after discharge, with close monitoring throughout.

Age: 18Years +All GendersPhase Not Applicable
25 locations

1-10 of 11

1